1. Chow SC, Endrenyi L, Lachenbruch PA, Mentre F. Scientific factors and current issues in biosimilar studies. J Biopharm Stat. 2014;24:1138–53.
2. FDA. Guidance on scientific considerations in demonstrating biosimilarity to a reference product. Silver Spring: The United States Food and Drug Administration; 2015.
3. FDA. Guidance for industry – process validation: general principles and practices, Current Good Manufacturing Practices (CGMP), Revision 1, the United States Food and Drug Administration, Rockville, Maryland, USA; 2011.
4. Christl L. Overview of regulatory pathway and FDA’s guidance for development and approval of biosimilar products in US. Presented at FDA ODAC meeting, January 7, 2015, Silver Spring, Maryland. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM436387.pdf .
5. Tsong Y, Dong X, Shen M. Development of statistical methods for analytical similarity assessment. J Biopharm Stat. 2015. doi: 10.1080/10543406.2015.1092038 .